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Abstract: Antiplatelet drugs are widely used for the prevention of
cardiovascular disease and cerebral vascular disorders. Although there
have been several studies on gastroduodenal mucosal injury with
gastrointestinal (GI) symptoms such as GI bleeding, in antiplatelet drug
users (including low-dose aspirin (LDA)), there have been few reports
on the association between antiplatelet drug use and gastroduodenal
mucosal injury in asymptomatic antiplatelet drug users. This study was a
cross-sectional study elucidating the association between antiplatelet
drug use and gastroduodenal mucosal injury in asymptomatic antiplate-
let drug users.
Subjects were 186 asymptomatic Japanese antiplatelet drug users
who underwent a regular health checkup. Subjects were divided into
those with and without gastroduodenal mucosal injury endoscopically,
and the association between gastroduodenal mucosal injury and other
data in asymptomatic antiplatelet drug users was investigated.
The prevalence of males and drinkers were significantly higher in
subjects with gastroduodenal mucosal injury than in those without. In
addition, the prevalence of proton pump inhibitor (PPI) users was
significantly lower in subjects with gastroduodenal mucosal injury than
in subjects without gastroduodenal mucosal injury. Logistic regression
analysis showed PPI (odds ratios: 0.116; 95% confidence intervals:
0.021–0.638; P< 0.05) was a significant predictor of a decreased
prevalence of gastroduodenal mucosal injury and closed-type (C-type)
atrophy (3.172; 1.322–7.609; P< 0.01) was a significant predictor of an
increased prevalence of severe gastroduodenal mucosal injury in
asymptomatic antiplatelet drug users.
Gender and lifestyle, such as drinking, may have an impact on risk of
gastroduodenal mucosal injury in asymptomatic subjects taking anti-
platelet drugs. Although PPI is a significant predictor of a decreased
prevalence of gastroduodenal mucosal injury, including in
asymptomatic antiplatelet drug users, status of gastric atrophy should
also be considered against severe gastroduodenal mucosal injury.
(Medicine 94(26):e1047)
Abbreviations: ALT = alanine aminotransferase, AST = aspartate
aminotransferase, BMI = body mass index, CI = confidence
interval, C-type = closed-type, CV = cardiovascular, DBP =
diastolic blood pressure, FPG = fasting plasma glucose, GGT = g-
glutamyl transpeptidase, GI = gastrointestinal, H. pylori =
Helicobacter pylori, H2-RA = histamine type 2-receptor
antagonist, HbA1c = hemoglobin A1c, HDL-C = high-density
lipoprotein cholesterol, IGT = impaired glucose tolerance, LDA =
low dose aspirin, LDL-C = low-density lipoprotein cholesterol,
MCV = mean corpuscular volume, MLS = modified Lanza score,
NGSP = National Glycohemoglobin Standardization Program, NS
= not significant, NSAID = nonsteroid antiinflammatory drug, OR
= odds ratio, O-type = open-type, P = probability, PPI = proton
pump inhibitor, SBP = systolic blood pressure, SD = standard
deviation, T-CHO = total cholesterol, TG = triglyceride, UA = uric
acid, WBC = white blood cell, WC = waist circumference.
INTRODUCTION
A ntiplatelet drugs have been widely administered for theprevention of cerebrovascular and cardiovascular (CV)
diseases in various patient populations.1–3 Although aspirin,
an antiplatelet drug, reduces the risk of major CV events,4 it is
known to lead to various upper gastrointestinal (GI) compli-
cations.5,6 Therefore, the recent increase in number of GI com-
plications, such as GI bleeding, because of the increase in use of
antiplatelet drugs, has become problematic. Although there have
been many reports on the association between antiplatelet drug
use, including low-dose aspirin (LDA), and GI events with
symptoms such as GI bleeding and perforation,7–13 there have
been few reports on the association between antiplatelet drug use
and gastroduodenal mucosal injury in asymptomatic subjects. In
this study, the association between antiplatelet drug use and
gastroduodenal mucosal injury in asymptomatic Japanese sub-
jects taking antiplatelet drugs was investigated.
METHODS
Study Subjects
Subjects were 7065 Japanese adults aged 21 to 85 years
who underwent a regular health checkup, including physical
examination, blood test screening, and upper GI endoscopy, at
our hospital from April 2010 to March 2013. Most subjects were
asymptomatic, healthy adults residing around Takamatsu city.
Subjects who had a history of digestive tract surgery, serious
hepatic, renal or pulmonary disorders, digestive symptom, such
as hematemesis, melena, abdominal pain, epigastralgia, chest
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pain, or back pain, or who were diagnosed with gastric or
esophageal cancer at the time of upper GI endoscopy were
excluded from this study. Subjects who had been taking anti-
platelet drugs (aspirin, clopidogrel, limaprostalfadex, ethyl ico-
sapentate, cilostazol, ticlopidine, dipyridamole, beraprost
sodium, and sarpogrelate hydrochloride) for at least 3 months
before checkup were defined as antiplatelet drug users. The
subject who took 81 to 100 mg daily aspirin was defined as taker
of LDA in this study. Body weight and height of the participants
were measured, and body mass index (BMI) was calculated.
Waist circumference (WC) was measured at the umbilical level.
Venous blood samples were taken from all subjects at approxi-
mately 0900 hours following a 12-h overnight fast, and the levels
of alanine aminotransferase (ALT), aspartate aminotransferase
(AST), g-glutamyl transpeptidase (GGT), total cholesterol (T-
CHO), triglyceride (TG), high-density lipoprotein cholesterol
(HDL-C), low-density lipoprotein cholesterol (LDL-C), uric acid
(UA), fasting plasma glucose (FPG), and hemoglobin A1c
(HbA1c) (National Glycohemoglobin Standardization Program
[NGSP]) were determined by common enzymatic methods using
an auto analyzer (TBA-80FR; Toshiba Medical System, Tokyo,
Japan). Helicobacter pylori infection was diagnosed by the
serological tests for anti-H. pylori immunoglobulin G using an
enzyme-linked immunosorbent assay (E Plate ‘Eiken’ H. pylori
antibody; Eiken Kagaku, Tokyo, Japan) or histological examin-
ation. Presence of H. pylori antibody was considered positive if
the antibody level was10 U/ml. All subjects were informed that
the clinical data obtained by medical checkup may be retro-
spectively analyzed, and informed consent was obtained. This
study was approved by the Ethics Committees of Kagawa Pre-
fectural Cancer Detection Center.
Upper GI Endoscopy
Upper GI endoscopy was performed in 7065 subjects who
underwent a regular health checkup and choose to undergo an
upper GI endoscopy rather than an upper GI series for assessment
of upper GI. Three endoscopy specialists who had more than 10
years of experience in endoscopy performed the endoscopic
procedures. All examiners performed the standard endoscopic
examination of the esophagus, stomach, and duodenum without
having the subject’s results of the blood test screening, physical,
and physiological examinations by using a conventional single-
channel endoscope (GIF-H260, -PQ260; Olympus, Tokyo, Japan).
Endoscopic Evaluation of Gastroduodenal
Mucosal Injury and Gastric Atrophy
The grade of gastroduodenal mucosal injury was assessed
according to the modified Lanza score (MLS).14–16 In this
scoring system, there are 5 grades of gastroduodenal mucosal
injury. Five grades of gastroduodenal mucosal injury are from 0
to 4: Grade 0 is normal mucosa; Grade 1 is erythema or
petechiae only; Grade 2 is 1 to 2 erosive lesions; Grade 3 is
3 to 10 erosive lesions, Grade 4 is more than 10 erosive lesions
or ulcer over the body, antrum, and proximal duodenum.
Gastroduodenal ulcer was defined by a mucosal break of
3 mm or greater in diameter with unequivocal depth. The longer
diameter of the lesion was measured by standard open-biopsy
forceps with an opened length of 6 mm. The score of MLS,
which was at least Grade 2, was considered as positive of
gastroduodenal mucosal injury in this study. In addition, the
score of MLS, which was at least Grade 3, was considered as
positive of severe gastroduodenal mucosal injury in this study.
During endoscopy, more than 30 endoscopic gastroduodenal
pictures covering the entire area of the stomach and the
duodenum were saved in the database. The MLS was graded
and independently validated by a single endoscopy specialist
who was blinded to any other information about the subjects. In
addition, extension of the endoscopic atrophic border was
evaluated, and the grade of atrophy was diagnosed according
to the criteria of Kimura and Takemoto.17 If the border was
shifted orally and did not exist on the lesser curvature, it was
defined as open type. If the border was on the lesser curvature of
the stomach, it was defined as closed type.
Statistical Analysis
This study was a cross-sectional study elucidating the
association between antiplatelet drug use and gastroduodenal
mucosal injury in asymptomatic antiplatelet drug users. All
statistical analyses were carried out using Med Calc Software
(Broekstraat, Mariakerke, Belgium). Data were expressed as
means standard deviation (SD) and summarized by the fre-
quency for categorical variables. A probability (P) value con-
sidered statistically significance was accepted as less than 0.05.
The x2-test or Student t-test was used to compare and determine
differences between two groups for independent samples, and P
value was adjusted for confounding variables using analysis of
covariance. Factors with a significant influence on the preva-
lence of gastroduodenal mucosal injury or severe gastroduode-
nal mucosal injury were then determined by univariate analysis.
And age, sex, BMI, and factors that had a P value of less than
0.15 by univariate analysis were then subjected to a multivariate
logistic regression analysis. The odds ratios (ORs) and 95%
confidence interval (CI) were analyzed for each variable.
RESULTS
Enrollment
Figure 1 shows the flow diagram of the enrolment of
subjects in this study. Of the 23,138 subjects who underwent
a regular health checkup from April 2010 to March 2013 at our
hospital, 7065 (30.5%) subjects underwent upper gastrointes-
tinal endoscopy. Of the 7065 subjects, 200 (2.8%) subjects took
some form of antiplatelet drug. Of the 200 subjects, 14 fulfilled
the exclusion criteria and were excluded, and the remaining 186
subjects were enrolled in this study.
Subject Characteristics
Subject characteristics are shown in Table 1; the pro-
portion of men was 77.4%, mean age was 63.7 7.5 years,
mean BMI was 24.3 3.7 kg/m2, and mean WC was
85.7 9.3 cm in all subjects (Table 1). Prevalence of hyperten-
sion, dyslipidemia, and impaired glucose tolerance (IGT) was
79.0%, 60.2%, and 29.6%, respectively. The proportion of
drinkers and current smokers was 64.5% and 8.1%, respect-
ively. The number of LDA, clopidogrel, ticlopidine, cilostazol,
ethyl icosapentate, limaprostalfadex, and multiple antiplatelet
drugs in antiplatelet drug users was 116, 18, 8, 15, 15, 18, and
22, respectively. The proportion of cerebral vascular disease
and ischemic heart disease in underlying disease was 29.0% and
25.3%, respectively.
Comparison of Clinical Characteristics Between
Subjects With and Without Gastroduodenal
Mucosal Injury
Comparison of clinical characteristics between subjects
with and without gastroduodenal mucosal injury is shown in
Table 2, in which the adjusted P value was adjusted for
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confounding variables, including age, BMI, WC, alcohol con-
sumption, and smoking habit. Of the 186 subjects, 61 had
gastroduodenal mucosal injury and the proportion of gastro-
duodenal mucosal injury in all subjects was 32.8%. The pro-
portion of men in the subjects with and without gastroduodenal
mucosal injury was 86.9% and 72.8%, respectively. The pro-
portion of men was significantly higher in subjects with gastro-
duodenal mucosal injury than in those without (P< 0.05). The
mean age in the subjects with and without gastroduodenal
mucosal injury was 63.7 8.0 years and 63.8 7.3 years,
respectively. The mean BMI in the subjects with and without
gastroduodenal mucosal injury was 24.3 3.6 kg/m2 and
24.3 3.8 kg/m2, respectively. The mean WC in the subjects
with and without gastroduodenal mucosal injury was
86.0 8.3 cm and 85.5 9.7 cm, respectively. There was no
significant difference in age, BMI, and WC between subjects
with and without gastroduodenal mucosal injury. The preva-
lence of hypertension in the subjects with and without gastro-
duodenal mucosal injury was 78.7% and 79.2%, respectively.
The prevalence of dyslipidemia in the subjects with and without
gastroduodenal mucosal injury was 63.9% and 58.4%, respect-
ively. The prevalence of IGT in the subjects with and without
gastroduodenal mucosal injury was 24.6% and 32.0%, respect-
ively. There was no significant difference in the prevalence of
hypertension, dyslipidemia, or IGT between subjects with and
without gastroduodenal mucosal injury. Uric acid in the subjects
with and without gastroduodenal mucosal injury was
6.2 1.3 mg/dl and 5.6 1.4 mg/dl, respectively. Uric acid
was significantly higher in subjects with gastroduodenal muco-
sal injury than in those without (P< 0.05). The proportion of
current smokers in the subjects with and without gastroduodenal
mucosal injury was 9.8% and 7.2%, respectively. The pro-
portion of LDA users in the subjects with and without gastro-
duodenal mucosal injury was 68.9% and 59.2%, respectively.
The proportion of anticoagulant drug users in the subjects with
and without gastroduodenal mucosal injury was 6.6% and 5.6%,
respectively. There was no significant difference in the pro-
portion of current smokers, LDA users, or anticoagulant drug
users between subjects with and without gastroduodenal muco-
sal injury. The proportion of drinkers in the subjects with and
without gastroduodenal mucosal injury was 75.4% and 59.2%,
respectively. The proportion of drinkers in subjects with
gastroduodenal mucosal injury was significantly higher than
in those without (P< 0.05). The proportion of PPI users in the
subjects with and without gastroduodenal mucosal injury was
3.3% and 14.4%, respectively. The proportion of PPI users in
subjects with gastroduodenal mucosal injury was significantly
lower than in those without (P< 0.05).
Predictors of Gastroduodenal Mucosal Injury
Univariate and multivariate independent predictors of
gastroduodenal mucosal injury in asymptomatic antiplatelet
drug users are shown in Table 3. Of the 28 items related to
the clinical background of subjects, sex, alcohol consumption,
and PPI use were identified as significant factors by univariate
analysis. Multiple logistic regression analysis was performed
using covariates of age, sex, BMI, and 6 items that had a Pvalue
of less than 0.15 by univariate analysis: HDL-C, AST, presence
of H. pylori, alcohol consumption, PPI use, and status of gastric
atrophy. Proton pump inhibitor use was a significant and
independent predictor of a decreased prevalence of gastroduo-
denal mucosal injury. The odds ratio (95% confidence interval,
P value) for gastroduodenal mucosal injury was as follow: PPI,
0.118 (0.022–0.637, P< 0.05).
Predictors of Severe Gastroduodenal Mucosal
Injury
Univariate and multivariate independent predictors of
severe gastroduodenal mucosal injury in asymptomatic anti-
platelet drug users are shown in Table 4. Of the 186 subjects, 33
had severe gastroduodenal mucosal injury and the proportion of
severe gastroduodenal mucosal injury in all subjects was 17.7%.
Of the 28 items related to the clinical background of subjects,
UA, and status of gastric atrophy were identified as significant
factors by univariate analysis. Multiple logistic regression
analysis was performed using covariates of age, sex, BMI,
and 5 items that had a P value of less than 0.15 by univariate
analysis: UA, alcohol consumption, LDA use, PPI use, and
status of gastric atrophy. Closed-type (C-type) gastric atrophy
was a significant and independent predictor of an increase
prevalence of severe gastroduodenal mucosal injury. The odds
ratio (95% confidence interval, p value) for severe gastroduo-
denal mucosal injury was as follow: C-type, 3.172 (1.322–
7.609, P< 0.01).
DISCUSSION
This study aimed to explore the association between
antiplatelet drug use and gastroduodenal mucosal injury in
asymptomatic antiplatelet drug users. Antiplatelet drugs,
including LDA, have been known to reduce the risk of CV
disease.1,3 Use of antiplatelet drugs has increased with the
recent rise in the number of elderly individuals in developed
countries, including in Japan. In addition, an increase in inci-
dence of GI complications, such as hematemesis, melena, and
ulcers, in antiplatelet drug users has become problematic.18–22
Although there have been many reports on the association
between antiplatelet drug use and GI events with symptoms
such as GI bleeding and perforation, the association between
antiplatelet drugs and gastroduodenal mucosal injury in asymp-
tomatic antiplatelet drug users remains unclear. To our knowl-
edge, this study is the first to demonstrate that in asymptomatic
antiplatelet drug users, the proportion of men and drinkers was
significantly higher in subjects with gastroduodenal mucosal
injury than in those without. In addition, PPI use was a
significant predictor of a decreased prevalence of
Subjects who underwent 
upper gastrointestinal 
endoscopy (n=7065)
Subjects who underwent 
a regular health check-up
(n=23138)
Subjects who did not undergo 
upper gastrointestinal 
endoscopy (n=16073)
(from April 2010 to March 2013 at our hospital)
Subjects who used anti-
platelet drugs
(n=200)











FIGURE 1. Flow diagram of subject enrollment in the current
study.
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gastroduodenal mucosal injury and C-type gastric atrophy was a
significant predictor of an increased prevalence of severe
gastroduodenal mucosal injury in asymptomatic antiplatelet
drug users.
Antiplatelet drugs have been known to easily cause GI
bleeding.1,23,24 Derry et al reported that the odds ratio of GI
bleeding in taking LDA was 1.51 to 1.68 against a placebo in a
metaanalysis of randomized controlled trials.25 An odds ratio of
7.7 was reported for upper GI bleeding among LDA users in a
recent Japanese case-controlled multicenter study.7 Moreover,
the cumulative incidence of recurrent bleeding in subjects with
healed ulcers was reported to be 8.6 % among patients who
received clopidogrel, and 0.7 % among those who received
aspirin plus esomeprazole.11 A 12 % incidence rate of GI
bleeding after a median follow-up of 1 year was reported in
patients who received clopidogrel and who had had previous
peptic ulcer disease.12 In addition, several studies have ident-
ified the use of nonsteroid anti-inflammatory drugs (NSAIDs),
LDA, and antithrombotic drugs as being a significant cause of
gastroduodenal ulcers.7,26–30 Therefore, the use of antiplatelet
therapy may be limited by the possibility of GI bleeding and
ulcers in patients with a history of GI events. Of the 33 subjects
with severe gastroduodenal mucosal injury, 17 had endoscopi-
cally observable gastroduodenal ulcers, and the prevalence of
endoscopically observable gastroduodenal ulcers in all subjects
was 9.1% in the current study. There, however, was no
TABLE 1. Subject Characteristics
Number 186
Sex (men/women) (% men) 144/42 (77.4%)
Age (years) 63.7 7.5
BMI (kg/m2) 24.3 3.7
WC (cm) 85.7 9.3
SBP (mmHg) 127.8 14.5
DBP (mmHg) 76.8 10.3
Hypertension (þ/) (% positive) 147/39 (79.0%)
T-CHO (mg/dl) 190.0 33.0
TG (mg/dl) 124.1 104.9
HDL-C (mg/dl) 59.2 15.5
LDL-C (mg/dl) 115.1 28.7
Dyslipidemia (þ/) (% positive) 112/74 (60.2%)
UA (mg/dl) 5.8 1.4
FPG (mg/dl) 108.4 22.9
HbA1c (% NGSP) 6.0 0.7
IGT (þ/) (% positive) 55/131 (29.6%)
Hb (g/dl) 14.2 1.4
MCV (fl) 92.1 4.7
ALT (IU/l) 24.6 13.3
AST (IU/l) 24.1 8.0
GGT (IU/l) 46.3 46.5
Presence of Helicobacter pylori (þ/) (% positive) 71/115 (38.2%)
Drinker/nondrinker (% drinker) 120/66 (64.5%)
Past history of smoking (þ/) (% positive) 112/74 (60.2%)
Current smoker (þ/) (% positive) 15/171 (8.1%)
Kind of antiplatelet drug (LDA/clopidogrel/ticlopidine/cilostazol/ethyl icosapentate/
limaprostalfadex/others/multiple antiplatelet drugs)
116/18/8/15/15/18/18/22
Gastric agents (þ/) (% positive) (PPI/H2-RA) 30/156 (16.1%) 19
(10.2%)/11 (5.9%)
Underlying diseases
Ischemic heart disease 47 (25.3%)
Cardiac dysrhythmias 17 (9.1%)
Other cardiac disease 5 (2.7%)
Cerebral vascular disease 54 (29.0%)
Other vascular disease 5 (2.7%)
Renal disease 13 (7.0%)
Orthopedic disease 18 (9.7%)
Collagen disease 3 (1.6%)
Other disease 4 (2.2%)
Data are meanSD.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma
glucose; GGT, g-glutamyl transpeptidase; H2-RA, histamine type 2-receptor antagonist; HbA1c, hemoglobin A1c;Hb, hemoglobin; HDL-C, high-
density lipoprotein cholesterol; IGT, impaired glucose tolerance; LDA, low dose aspirin; LDL-C, low-density lipoprotein cholesterol; MCV, mean
corpuscular volume; NGSP, National Glycohemoglobin Standardization Program; PPI, proton pump inhibitor; SBP, systolic blood pressure; T-
CHO, total cholesterol; TG, triglyceride; UA, uric acid; WC, waist circumference.
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incidence of bleeding during upper GI endoscopy. In addition,
the prevalence of endoscopically observable gastroduodenal
ulcers was 40% in subjects with a history of previous peptic
ulcer disease, demonstrating that the current results were similar
to previous reports.
Gastric mucosal injury induced by antiplatelet drugs has
been known to be not necessarily associated with gastric events
and digestive symptoms, such as hematemesis, melena, and
abdominal pain. In addition, most endoscopically determined
peptic ulcers induced by long-term NASID treatment including
antiplatelet drugs, have been known to be generally asympto-
matic or minimally symptomatic.20,31,32 If overt bleeding signs,
such as hematemesis and melena, and/or digestive symptoms,
such as abdominal pain, occur in patients taking antiplatelet
drugs, it is likely that most of these patients would go to a
medical institution. Asymptomatic gastroduodenal mucosal
injury induced by antiplatelet drugs, however, may easily be
missed because of the absence of bleeding signs and digestive
symptoms. The frequency of gastroduodenal mucosal injury
observed in the current study may be similar to the real
frequency of gastroduodenal mucosal injury without digestive
symptoms, because participants in the current study underwent
upper GI endoscopy and had no digestive symptoms or events.
The range in frequency of abdominal symptoms in antiplatelet
drug users has been reported to be very wide. In the current
study, 6% of antiplatelet drug users had digestive symptoms and
underwent a regular health checkup (data not shown). This
discrepancy in the proportion of antiplatelet drug users with
abdominal symptoms may be because of differences between
studies, including whether the subjects were representative of









Age (years) 63.7 8.0 63.8 7.3 NS
Sex (men/women) (% men) 53/8 (86.9%) 91/34 (72.8%) <0.05
BMI (kg/m2) 24.3 3.6 24.3 3.8 NS
WC (cm) 86.0 8.3 85.5 9.7 NS
SBP (mmHg) 127.5 15.8 128.0 13.9 (NS)
DBP (mmHg) 76.6 9.5 77.0 10.7 (NS)
Hypertension (þ/) (% positive) 48/13 (78.7%) 99/26 (79.2%) (NS)
T-CHO (mg/dl) 186.6 30.5 191.7 34.1 (NS)
TG (mg/dl) 117.4 65.0 127.4 119.7 (NS)
HDL-C (mg/dl) 58.1 14.0 59.8 16.2 (NS)
LDL-C (mg/dl) 113.5 25.6 115.9 30.2 (NS)
Dyslipidemia (þ/) (% positive) 39/22 (63.9%) 73/52 (58.4%) (NS)
UA (mg/dl) 6.2 1.3 5.6 1.4 (<0.05)
FPG (mg/dl) 109.0 28.6 108.1 19.6 (NS)
HbA1c (% NGSP) 6.0 0.8 5.9 0.6 (NS)
IGT (þ/) (% positive) 15/46 (24.6%) 40/85 (32.0%) (NS)
WBC (ml) 6090 2183 5699 1398 (NS)
Hb (g/dl) 14.3 1.2 14.1 1.4 (NS)
MCV (fl) 92.5 3.5 91.8 5.2 (NS)
ALT (IU/l) 25.4 13.8 24.3 13.1 (NS)
AST (IU/l) 25.3 8.6 23.6 7.7 (NS)
GGT (IU/l) 46.7 44.9 46.0 47.4 (NS)
Drinker/nondrinker (% drinker) 46/15 (75.4%) 74/51 (59.2%) <0.05
Current smoker (þ/) (% positive) 6/55 (9.8%) 9/116 (7.2%) NS
Presence of Helicobacter pylori (þ/) (% positive) 18/43 (29.5%) 53/72 (42.4%) (NS)
LDA (þ/) (% positive) 42/19 (68.9%) 74/51 (59.2%) (NS)
Multiple antiplatelet drugs (þ/) (% positive) 6/55 (9.8%) 17/108 (13.6%) (NS)
Anticoagulant drug (þ/) (% positive) 4/57 (6.6%) 7/118 (5.6%) (NS)
Gastric atrophy (C-type/O-type) (% C-type) 22/39 (36.1%) 30/95 (24.0%) (NS)
Past history of peptic ulcer (þ/) (% positive) 13/48 (21.3%) 22/103 (17.6%) (NS)
PPI (þ/) (% positive) 2/59 (3.3%) 18/107 (14.4%) (<0.05)
H2-RA (þ/) (% positive) 5/56 (8.2%) 6/119 (4.8%) (NS)
Data are meanSD.
P value is based on the x2 test or Student t-test. Significant is at the 5% level.
yAdjusted for age, sex, BMI, WC, alcohol consumption, and smoking habit.AST, aspartate aminotransferase; AUT, alanine aminotransferase; BMI,
body mass index; C-type, closed type; DBP, diastolic blood pressure; FPG, fasting plasma glucose; GGT g-glutamyl transpeptidase; H2-RA,
histamine type 2-receptor antagonist; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; IGT, impaired glucose tolerance; LDA,
low dose aspirin; LDL-C, low-density lipoprotein cholesterol; MCV,mean corpuscular volume; NGSP, National Glycohemoglobin Standardization
Program; NS, not significant; O-type, open type; PPI, proton pump inhibitor; SBP, systolic blood pressure; T-CHO, total cholesterol; TG, triglyceride;
UA, uric acid; WBC, white blood cell; WC, waist circumference.
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the general population, had underlying disease, underwent
regular medical checkup, or underwent upper GI endoscopy,
and differences in lifestyle backgrounds.
Low-dose aspirin, an antiplatelet drug, can cause mucosal
injury and potential bleeding directly as well as by COX
inhibition.33 Although antiplatelet drugs, including LDA, have
a possibility of causing GI bleeding, the prevalence of GI
bleeding is lower in users of antiplatelet drugs other than
LDA. Hallas et al13 reported that administration of clopidogrel,
an antiplatelet drug, did not have a significant risk of causing GI
bleeding in a case-controlled study. On the contrary, the use of
clopidogrel in patients with previous peptic ulcer disease was
reported to have a high incidence of GI bleeding.12 The
association between antiplatelet drug use and GI mucosal injury
in asymptomatic subjects has been unclear. Although there have
been many reports on the association between antiplatelet drug
use and GI injury, most reports did not make a distinction
between subjects with and without symptoms. Thus, to clarify
possible differences between subjects with and without gastro-
duodenal mucosal injury, we simply divided asymptomatic
antiplatelet drug users into those with or without gastroduodenal
mucosal injury, using upper GI endoscopy during a normal
medical checkup. In the current study, the prevalence of gastro-
duodenal mucosal injury was 32.8%, and the prevalence of
endoscopically gastroduodenal ulcer was 9.1%. LDA use was
not a significant factor for prevalence of gastroduodenal muco-
sal injury in asymptomatic antiplatelet drug users. Of the 17
subjects who, however, had an endoscopically observable gas-
troduodenal ulcer, 12 (88.2%) were LDA users. These results
suggest that LDA use may increase the risk of deep mucosal
injury compared with other antiplatelet drugs.
The association between H. pylori infection and GI injury
among antiplatelet drug users has remained controversial.
Shiotani et al34 reported that there was no association between
H. pylori infection and the presence of peptic ulcers among
patients taking LDA. An Italian study, however, reported that
TABLE 3. Results of Univariate and Multivariate Analyses: Independent Predictors of Gastroduodenal Mucosal Injury in
Asymptomatic Antiplatelet Drug Users




() (N¼ 125) P Value OR 95% CI P Valuey
Age (3 65/< 65 years) 27/34 59/66 NS 0.970 0.495–1.901 NS
Sex (men/women) 53/8 91/34 <0.05 1.749 0.650–4.711 NS
BMI (3 25/< 25 kg/m2) 20/41 50/75 NS 0.643 0.315–1.312 NS
WC (3 85/<85 cm) 35/26 69/56 NS
SBP (3 130/<130 mmHg) 29/32 53/72 NS
DBP (3 90/<90 mmHg) 6/55 13/112 NS
Hypertension (þ/) 48/13 99/26 NS
T-CHO (3 220/<220 mg/dl) 7/54 25/100 NS
TG (3 150/<150 mg/dl) 13/48 31/94 NS
HDL-C (<40/3 40 mg/dl) 8/53 6/119 NS 3.571 0.937–13.61 NS
LDL-C (3 140/<140 mg/dl) 9/52 25/100 NS
Dyslipidemia (þ/) 39/22 73/52 NS
UA (3 7.0/<7.0 mg/dl) 18/43 24/101 NS
FPG (3 110/<110 mg/dl) 15/46 38/87 NS
HbA1c (3 6.2/<6.2 % NGSP) 16/45 30/95 NS
IGT (þ/) 15/46 40/85 NS
ALT (3 31/<31 IU/l) 15/46 25/100 NS
AST (3 31/<31 IU/l) 15/46 18/107 NS 1.836 0.759–4.442 NS
GGT (3 51/<51 IU/l) 16/45 31/94 NS
Presence of Helicobacter pylori (þ/) 18/43 53/72 NS 0.684 0.319–1.467 NS
Drinker/nondrinker 46/15 74/51 <0.05 1.255 0.549–2.871 NS
Current smoker (þ/) 6/55 9/116 NS
LDA (þ/) 42/19 74/51 NS
Anticoagulant (þ/) 4/57 7/118 NS
PPI (þ/) 2/59 18/107 <0.05 0.118 0.022–0.637 <0.05
H2-RA (þ/) 5/56 6/119 NS
Gastric atrophy (C-type/O-type) 22/39 30/95 NS 1.843 0.842–4.035 NS
Past history of peptic ulcer (þ/) 13/48 22/103 NS

P value is based on the univariate analysis.
yP value is based on the multivariate logistic regression analysis. Significant is at the 5% level.ALT, alanine aminotransferase; AST, aspartate
aminotransferase; BMI, body mass index; CI, confidence interval; C-type, closed type; DBP, diastolic blood pressure; FPG, fasting plasma glucose;
GGT, g-glutamyl transpeptidase; H2-RA, histamine type 2-receptor antagonist; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein
cholesterol; IGT, impaired glucose tolerance; LDA, low dose aspirin; LDL-C, low-density lipoprotein cholesterol; NGSP, National Glycohemoglobin
Standardization Program; NS, not significant; OR, odds ratio; O-type, open type; PPI, proton pump inhibitor; SBP,systolic blood pressure; T-CHO,
total cholesterol; TG, triglyceride; UA, uric acid; WC, waist circumference.
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the prevalence of peptic ulcers was significantly higher among
H. pylori-positive subjects than among H. pylori-negative sub-
jects in elderly, symptomatic chronic users of LDA.35 In
addition, it was reported that there was no significant difference
in the prevalence of previous H. pylori infection between with
and without GI bleeding in patients with previous peptic ulcer
disease.12 The current study showed that in antiplatelet drug
users, there was no significant difference in the prevalence of H.
pylori infection between those with and without gastroduodenal
mucosal injury. In addition, in LDA users, there was no
significant difference in the prevalence of H. pylori infection
between those with and without gastroduodenal mucosal injury
(data not shown). The discrepancy between H. pylori infection
and presence of peptic ulcers or gastric mucosal injury in
antiplatelet drug users may be because of differences in the
severity of H. pylori gastritis, and topography of the gastritis
among the subjects of each study.36 Antral-predominant gas-
tritis is associated with increased acid secretion, which may
increase gastric mucosal injury, whereas corpus-predominant
gastritis is associated with reduced acid secretion and thus may
reduce gastric mucosal injury.36,37 Interestingly, the current
study showed that there was a tendency of increased prevalence
of C-type atrophy in subjects with gastroduodenal mucosal
injury (36.1%) than in those without (24.0%) and C-type
atrophy was a significant and independent predictor of an
increased prevalence of severe gastroduodenal mucosal injury.
In addition, the prevalence of gastroduodenal mucosal injury in
subjects with C-type atrophy was significantly higher than in
subjects with O-type atrophy among antiplatelet drug users with
H. pylori infection in current study (data not shown). It was
reported that the effect of H. pylori infection on the aspirin-
induced gastropathy was biphasic depending on the individual
gastric acid secretion.38 In other words, the presence of suffi-
cient amounts of gastric acid, H. pylori infection, and aspirin
may cause a synergistically damage gastric mucosal. Our results
suggest that C-type atrophy may increase the risk of severe
TABLE 4. Results of Univariate and Multivariate Analyses: Independent Predictors of Severe Gastroduodenal Mucosal Injury in
Asymptomatic Antiplatelet Drug Users
Univariate Analysis Multivariate Analysis
Severe Mucosal
Injury (þ) (N¼ 33)
Mucosal injury
() (N¼ 125) P Value OR 95% CI P Valuey
Age (3 65/<65 years) 13/20 59/66 NS 1.099 0.449–2.688 NS
Sex (men/women) 29/4 91/34 NS 1.702 0.465–6.229 NS
BMI (3 25/< 25 kg/m2) 9/24 50/75 NS 0.459 0.180–1.169 NS
WC (3 85/<85 cm) 19/14 69/56 NS
SBP (3 130/<130 mmHg) 15/18 53/72 NS
DBP (3 90/<90 mmHg) 2/31 13/112 NS
Hypertension (þ/) 24/9 99/26 NS
T-CHO (3 220/<220 mg/dl) 4/29 25/100 NS
TG (3 150/<150 mg/dl) 8/25 31/94 NS
HDL-C (< 40/3 40 mg/dl) 2/31 6/119 NS
LDL-C (3 140/<140 mg/dl) 6/27 25/100 NS
Dyslipidemia (þ/) 21/12 73/52 NS
UA (3 7.0/<7.0 mg/dl) 13/20 24/101 <0.05 2.158 0.822–5.667 NS
FPG (3 110/<110 mg/dl) 7/26 38/87 NS
HbA1c (3 6.2/<6.2 % NGSP) 6/26 30/95 NS
IGT (þ/) 7/26 40/85 NS
ALT (3 31/<31 IU/l) 7/26 25/100 NS
AST (3 31/<31 IU/l) 7/26 18/107 NS
GGT (3 51/<51 IU/l) 7/26 31/94 NS
Presence of Helicobacter pylori (þ/) 11/22 53/72 NS
Drinker/nondrinker 25/8 74/51 NS 1.131 0.419–3.055 NS
Current smoker (þ/) 4/29 9/116 NS
LDA (þ/) 26/7 74/51 NS 2.170 0.803–5.865 NS
Anticoagulant (þ/) 2/31 7/118 NS
PPI (þ/) 1/32 18/107 NS 0.144 0.017–1.207 NS
H2-RA (þ/) 3/30 6/119 NS
Gastric atrophy (C-type/O-type) 16/17 30/95 <0.05 3.172 1.322–7.609 <0.01
Past history of peptic ulcer (þ/) 7/26 22/103 NS

P value is based on the univariate analysis.
yP value is based on the multivariate logistic regression analysis. Significant is at the 5% level.ALT, alanine aminotransferase; AST, aspartate
aminotransferase; BMI, body mass index; CI, confidence interval; C-type, closed type; DBP, diastolic blood pressure; FPG, fasting plasma glucose;
GGT, g-glutamyl transpeptidase; H2-RA, histamine type 2-receptor antagonist; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein
cholesterol; IGT, impaired glucose tolerance; LDA, low dose aspirin; LDL-C, low-density lipoprotein cholesterol; NGSP, National Glycohemoglobin
Standardization Program; NS, not significant; OR, odds ratio; O-type, open type; PPI, proton pump inhibitor; SBP, systolic blood pressure; T-CHO,
total cholesterol; TG, triglyceride; UA, uric acid; WC, waist circumference.
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mucosal injury than O-type atrophy because of increased acid
secretion in even antiplatelet drugs users. Furthermore, studies
are needed to elucidate the mechanism of association between
gastric acid secretion level, status of gastric atrophy, H. pylori
infection, and antiplatelet drugs, because gastric acid secretion
levels were not measured in the current study.
Although there have been no prospective clinical trials
showing PPI use significantly preventing NSAID-associated
upper GI complications, PPIs are effective at reducing the risk
of endoscopic peptic ulcer.37,39 In addition, an epidemiological
study reported that PPI use was associated with an 80% decrease
in the risk of upper GI bleeding in LDA users.40 Shiotani et al34
reported that in LDA users, the proportion of PPI users was
significantly lower in those with peptic ulcer than in those
without. The current study showed that in asymptomatic anti-
platelet drug users, the proportion of PPI users was significantly
lower in those with gastroduodenal mucosal injury (3.3%) than
in those without (14.4%), and that PPI use was a significant
predictor of a decreased prevalence of gastroduodenal injury, in
confirmation with previous studies.
The association between drinking and gastric mucosal
injury, including peptic ulcers, remains controversial. Although
excess alcohol consumption is believed to cause GI injury,41 a
previous study reported that in NSAID users, the risk of upper
GI bleeding in nondrinkers was higher than in light drinkers.42
Light drinking in NSAID users may induce adaptive cytopro-
tection, a mechanism of protection against upper GI bleed-
ing.43,44 The current study, however, showed that subjects with
gastroduodenal mucosal injury had a higher proportion of
drinkers than in those without gastroduodenal mucosal injury.
In addition, alcohol consumption was not a significant protec-
tive factor against gastroduodenal mucosal injury in asympto-
matic antiplatelet drug users.
There were several limitations to the current study. First,
full evaluation of the cause-and-effect relationship between
gastroduodenal mucosal injury and use of antiplatelet drugs
was not performed, because the current study was of a cross-
sectional design. Second, of the 23,138 subjects who underwent
a regular health checkup, 16,073 subjects did not undergo upper
GI endoscopy (Fig. 1), because the Japanese who undergo a
medical checkup often choose to undergo an upper gastroin-
testinal series rather than an upper GI endoscopy. Third, there
was a possibility of selection bias, because most participants in
the current study were healthy individuals who underwent a
normal medical checkup. Furthermore studies are needed to
resolve these limitations.
In conclusion, the current study showed that in asympto-
matic antiplatelet drug users, there were significant differences
in sex, UA, proportion of drinkers, and PPI users between those
with and without gastroduodenal mucosal injury. Although PPI
use is an important protective factor against gastroduodenal
mucosal injury, including in antiplatelet drug users without
digestive symptoms, status of gastric atrophy should also be
considered against severe gastroduodenal mucosal injury.
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